Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emilio A Emini

Showing results (41-50 of 81) with videos related to

Pageof 9
Sort By:
The Pediatric Infectious Disease Journal|August 16, 2014
Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine manufactured with and without polysorbate 80 given to healthy infants at 2, 3, 4 and 12 months of ageJanusz Gadzinowski, Susan P Tansey, Jacek Wysocki, et al.
Bioorganic & Medicinal Chemistry Letters|August 6, 2002
Indinavir analogues with blocked metabolism sites as HIV protease inhibitors with improved pharmacological profiles and high potency against PI-resistant viral strainsYuan Cheng, Fengqi Zhang, Thomas A Rano, et al.
Vaccine|June 28, 2011
Immunogenicity of a combination vaccine containing diphtheria toxoid, tetanus toxoid, three-component acellular pertussis, hepatitis B, inactivated polio virus, and Haemophilus influenzae type b when given concomitantly with 13-valent pneumococcal conjugate vaccineFrancisco Gimenez-Sanchez, Dorothee M Kieninger, Kathrin Kueper, et al.
Vaccine|September 6, 2013
Evaluation of 13-valent pneumococcal conjugate vaccine and concomitant meningococcal group C conjugate vaccine in healthy infants and toddlers in SpainJavier Diez-Domingo, Alejandra Gurtman, Enrique Bernaola, et al.
The Pediatric Infectious Disease Journal|November 30, 2012
Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in healthy infants and toddlers given with routine vaccines in IndiaYeshwant K Amdekar, Sanjay K Lalwani, Ashish Bavdekar, et al.
Bioorganic & Medicinal Chemistry Letters|July 11, 2003
HIV protease inhibitors with picomolar potency against PI-Resistant HIV-1 by extension of the P3 substituentJoseph L Duffy, Thomas A Rano, Nancy J Kevin, et al.
Bioorganic & Medicinal Chemistry Letters|September 3, 2003
HIV-1 protease inhibitors with picomolar potency against PI-resistant HIV-1 by modification of the P1' substituentJoseph L Duffy, Brian A Kirk, Nancy J Kevin, et al.
Bioorganic & Medicinal Chemistry Letters|August 6, 2002
Synthesis and activity of novel HIV protease inhibitors with improved potency against multiple PI-resistant viral strainsJoseph L Duffy, Nancy J Kevin, Brian A Kirk, et al.
Bioorganic & Medicinal Chemistry Letters|November 1, 2003
Novel HIV-1 protease inhibitors active against multiple PI-resistant viral strains: coadministration with indinavirNancy J Kevin, Joseph L Duffy, Brian A Kirk, et al.
Journal of the American Chemical Society|October 27, 2018
3'-Tetrahydrofuranylglycine as a Novel, Unnatural Amino Acid Surrogate for Asparagine in the Design of Inhibitors of the HIV ProteaseWayne J Thompson, Arun K Ghosh, M Katharine Holloway, et al.
Pageof 9

Showing results (41-50 of 81) with videos related to

Sort By:
Pageof 9
The Pediatric Infectious Disease Journal|August 16, 2014
Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine manufactured with and without polysorbate 80 given to healthy infants at 2, 3, 4 and 12 months of ageJanusz Gadzinowski, Susan P Tansey, Jacek Wysocki, et al.
Bioorganic & Medicinal Chemistry Letters|August 6, 2002
Indinavir analogues with blocked metabolism sites as HIV protease inhibitors with improved pharmacological profiles and high potency against PI-resistant viral strainsYuan Cheng, Fengqi Zhang, Thomas A Rano, et al.
Vaccine|June 28, 2011
Immunogenicity of a combination vaccine containing diphtheria toxoid, tetanus toxoid, three-component acellular pertussis, hepatitis B, inactivated polio virus, and Haemophilus influenzae type b when given concomitantly with 13-valent pneumococcal conjugate vaccineFrancisco Gimenez-Sanchez, Dorothee M Kieninger, Kathrin Kueper, et al.
Vaccine|September 6, 2013
Evaluation of 13-valent pneumococcal conjugate vaccine and concomitant meningococcal group C conjugate vaccine in healthy infants and toddlers in SpainJavier Diez-Domingo, Alejandra Gurtman, Enrique Bernaola, et al.
The Pediatric Infectious Disease Journal|November 30, 2012
Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in healthy infants and toddlers given with routine vaccines in IndiaYeshwant K Amdekar, Sanjay K Lalwani, Ashish Bavdekar, et al.
Bioorganic & Medicinal Chemistry Letters|July 11, 2003
HIV protease inhibitors with picomolar potency against PI-Resistant HIV-1 by extension of the P3 substituentJoseph L Duffy, Thomas A Rano, Nancy J Kevin, et al.
Bioorganic & Medicinal Chemistry Letters|September 3, 2003
HIV-1 protease inhibitors with picomolar potency against PI-resistant HIV-1 by modification of the P1' substituentJoseph L Duffy, Brian A Kirk, Nancy J Kevin, et al.
Bioorganic & Medicinal Chemistry Letters|August 6, 2002
Synthesis and activity of novel HIV protease inhibitors with improved potency against multiple PI-resistant viral strainsJoseph L Duffy, Nancy J Kevin, Brian A Kirk, et al.
Bioorganic & Medicinal Chemistry Letters|November 1, 2003
Novel HIV-1 protease inhibitors active against multiple PI-resistant viral strains: coadministration with indinavirNancy J Kevin, Joseph L Duffy, Brian A Kirk, et al.
Journal of the American Chemical Society|October 27, 2018
3'-Tetrahydrofuranylglycine as a Novel, Unnatural Amino Acid Surrogate for Asparagine in the Design of Inhibitors of the HIV ProteaseWayne J Thompson, Arun K Ghosh, M Katharine Holloway, et al.
Pageof 9